ライフサイエンスコーパス: VMA

1 VMA area was positively associated with younger age and

2 VMA may affect the optic disc, macular parameters, and c

3 VMA was present in 101 (25.1%) eyes with exudative AMD,

4 s were +4.7 (PVD), +3.2 (RELEASE), and -0.2 (VMA) in the quarterly regimen and +4.9 (PVD), +12.7 (REL

5 At month 6, among the 26 VMA+ eyes (at baseline), 7 eyes demonstrated PVD, 17 eye

6 of vitreomacular contact (RELEASE; n = 48), VMA (n = 37), or PVA (n = 4).

7 n and +4.9 (PVD), +12.7 (RELEASE), and +7.5 (VMA) in the monthly regimen.

8 to identify the presence (VMA+) or absence (VMA-) of VMA.

9 A greater proportion of patients achieved VMA resolution and total PVD at month 12 with ocriplasmi

10 in ocriplasmin-treated patients who achieved VMA resolution at day 28.

11 ated and resulted in more patients achieving VMA resolution and PVD with less anti-VEGF use compared

12 -toprorenin ratio and vanillylmandelic acid (VMA) excretion (P < 0.025), tests of sympathetic nerve f

13 5(OH)2D3, and urinary vanillylmandelic acid (VMA) were measured by ELISA, and serum and urinary phosp

14 ue, here we turned to visuomotor adaptation (VMA)-a type of motor learning involving skill recalibrat

15 patients with focal vitreomacular adhesion (VMA) and exudative age-related macular degeneration (AMD

16 ar AMD who presented vitreomacular adhesion (VMA) detected by spectral-domain optical coherence tomog

17 ss the prevalence of vitreomacular adhesion (VMA) in consecutive naive eyes diagnosed with exudative

18 The impact of vitreomacular adhesion (VMA) resolution on patient-reported visual function in s

19 r traction (VMT) and vitreomacular adhesion (VMA), fluid, and central thickness.

20 al attachment (PVA), vitreomacular adhesion (VMA), partial vitreous detachment without vitreomacular

21 sted for presence of vitreomacular adhesion (VMA), width of vitreous adhesion (focal <1500 mum versus

22 tment of symptomatic vitreomacular adhesion (VMA)/vitreomacular traction, including full-thickness ma

23 lytic asymmetric vinylogous Mukaiyama aldol (VMA) reaction applicable to linear aliphatic aldehydes a

24 KA) acute angle: varus mechanical alignment (VMA) group (HKA < - 3 ) and neutral mechanical axis (NMA

25 wer laws led to the variance-mass allometry (VMA), which states that larger species have lower spatia

26 this relationship "variance-mass allometry" (VMA).

27 rly treatment in the RELEASE (P = 0.008) and VMA (P = 0.043) groups.

28 alence of VMA was 22.6% (CI, 21.1-24.2), and VMA area ranged from 0.25 to 42.7 mm(2) (mean, 12.53 mm(

29 Comparisons of HSS between NMA group and VMA group were performed.

30 detail to estimate the prevalence of VMA and VMA area detailing size and location of VMA.

31 6.67 and 6.86+/-7.58 letters in the VMA+ and VMA- groups, respectively (P = 0.007).

32 .31 and -161.84+/-131.34 mum in the VMA+ and VMA- groups, respectively (P = 0.681).

33 In eyes in the CATT, VMT and VMA were infrequent.

34 n binding in ventromedial hypothalamic area (VMA), medial basal hypothalamic area (MBA), arcuate nucl

35 At baseline, 26 patients were classified as VMA+ and 98 patients were classified as VMA-.

36 d as VMA+ and 98 patients were classified as VMA-.

37 tical meridian (vertical meridian asymmetry [VMA]).(3)(,)(4)(,)(5)(,)(6)(,)(7)(,)(8)(,)(9)(,)(10)(,)(

38 tical meridian (vertical-meridian asymmetry, VMA).

39 tical meridian (vertical meridian asymmetry, VMA).

40 r with SD-OCT than TD-OCT to detect baseline VMA (kappa 0.6 vs. 0.52); FTMH (kappa 0.9 vs. 0.78); and

41 We found that both VMA and IVMA engaged the left posterior hippocampus in a

42 A detailed VMA analysis was performed on a subsample consisting of

43 ith FTMH, phakic eyes, and eyes with a focal VMA </= 1500 mum.

44 eveloped PVD were classified as having focal VMA, with the diameter of vitreous attachment ranging fr

45 atients with nonsurgical resolution of focal VMA at day 28, nonsurgical full-thickness macular hole (

46 ry subgroups without them: presence of focal VMA, presence of FTMH, absence of ERM, and phakic lens s

47 Eyes with focal VMA have a greater chance to develop PVD than eyes with

48 ent agreement was 97%, 92%, 95%, and 82% for VMA, vitreous adhesion width, FTMH, and ERM, respectivel

49 Team grading reproducibility for VMA (kappa 0.91, 95% confidence interval [CI] 0.81-1.00)

50 emonstrated PVD, 17 eyes showed no change in VMA status, and 2 eyes were not gradable and were exclud

51 city associated with memory consolidation in VMA and an implicit-only version (IVMA).

52 s, Compared with NMA group, the HSS score in VMA group decreased by 0.81 units (95% CI, - 3.37 to 1.7

53 Secondary end points reported included VMA release over time, total posterior vitreous detachme

54 Macaque performance revealed an inverted VMA-their sensitivity was poorest in the lower vertical

55 Human observers showed a large VMA-their sensitivity was poorest at the upper vertical

56 vinyl monomers including vinyl methacrylate (VMA), allyl methacrylate (AMA), 4-vinylbenzyl methacryla

57 inyl monomers, including vinyl methacrylate (VMA), allyl methacrylate (AMA), and N,N-diallyl acrylami

58 and -136 mum (RELEASE), and -93 and -87 mum (VMA) in the monthly and quarterly regimens, respectively

59 the reader-determined presence or absence of VMA (96.7%), FTMH (97.1%), and all other baseline parame

60 NV development in the presence or absence of VMA (P = 0.0966).

61 The stage, size, and presence or absence of VMA were documented for each MH.

62 We recorded the vitreomacular angle of VMA nasally and temporally, the horizontal diameter of V

63 o develop PVD than eyes with a broad area of VMA.

64 y and temporally, the horizontal diameter of VMA, macular thickness, visual acuity, photoreceptor lay

65 cellent agreement for the study endpoints of VMA resolution (95.4%) and FTMH closure (100%) at day 28

66 line OCT features and the study endpoints of VMA resolution and FTMH closure.

67 and VMA area detailing size and location of VMA.

68 nd the theoretically predicted parameters of VMA, using detailed data on individual oak trees (Quercu

69 The opposite pattern of VMA in macaques and humans revealed in this study may re

70 Inclusion criteria included presence of VMA and best-corrected visual acuity (BCVA) of 20/32 or

71 Therefore, the presence of VMA should not preclude patients with DME from receiving

72 in more detail to estimate the prevalence of VMA and VMA area detailing size and location of VMA.

73 significant difference in the prevalence of VMA in eyes affected by AMD compared with age-matched co

74 The prevalence of VMA was 22.6% (CI, 21.1-24.2), and VMA area ranged from

75 fter treatment with ocriplasmin, the rate of VMA/VMT resolution was 45.8% (95% confidence interval [C

76 Spontaneous release of VMA (RVMA) was found in 15 (15.3%) eyes with exudative A

77 Resolution of VMA at day 28 was achieved more often in younger patient

78 ify the presence (VMA+) or absence (VMA-) of VMA.

79 e feasible, whereas patients with RELEASE or VMA may benefit from intensive retreatment.

80 9 +/- 0.4 (P = 0.02) for eyes without VMT or VMA (n = 377).

81 ed in a lower percentage of eyes with VMT or VMA at baseline (11.7%) than with neither condition (22.

82 Eyes with VMT or VMA treated as needed required on average 2 more injecti

83 At baseline and follow-up, VMT or VMA were not associated with VA.

84 with neither (n = 972), patients with VMT or VMA were younger (mean +/- standard error, 75.5 +/- 0.6

85 aseline, 143 patient eyes (12.8%) had VMT or VMA.

86 A total of 118 eyes remained with persistent VMA.

87 In the ocriplasmin group, pharmacologic VMA resolution at day 28 was higher in subgroups with th

88 met its primary end point with pharmacologic VMA resolution at day 28 being significantly higher in t

89 he proportion of subjects with pharmacologic VMA resolution at day 28.

90 A with 90-94% [mm], while the polymerization VMA is least stereospecific.

91 the baseline visit to identify the presence (VMA+) or absence (VMA-) of VMA.

92 (intein) from Saccharomyces cerevisiae (Sce VMA intein) in conjunction with a chitin-binding domain

93 sed on the observation that the modified Sce VMA intein can be induced to undergo a self-cleavage rea

94 1 intein switches, temperature-sensitive Sce VMA mutations that splice only at the permissive tempera

95 hat the N- and C-terminal regions of the Sce VMA intein may form a separate domain that is not only c

96 e have recently reported an engineered split VMA intein whose splicing activity in trans between two

97 aromyces cerevisiae vacuolar ATPase subunit (VMA) intein inserted within Gal4 and transferred these i

98 ent (intein) of the vacuolar ATPase subunit (VMA) of Saccharomyces cerevisiae catalyzes both protein

99 g the intein of the vacuolar ATPase subunit (VMA) of Saccharomyces cerevisiae that involves cysteines

100 led, 480 were determined to have symptomatic VMA/VMT at baseline post-CRC assessment.

101 ient-reported visual function in symptomatic VMA/vitreomacular traction (VMT) has not yet been docume

102 ient-reported visual function in symptomatic VMA/VMT.

103 providing improved resolution of symptomatic VMA compared with previous phase 3 trials with no additi

104 onths and included resolution of symptomatic VMA, closure of full-thickness macular hole (FTMH), mean

105 Patients with symptomatic VMA/VMT at baseline determined by CRC were included in b

106 well tolerated in patients with symptomatic VMA/VMT in a real-world setting.

107 Patients with symptomatic VMA/VMT were randomly assigned (2:1 or 3:1 in study TG-M

108 A total of 652 patients with symptomatic VMA/VMT, including when associated with a macular hole 4

109 The results of this study suggest that VMA might be a consequence rather than a causative facto

110 The VMA has been predicted through theoretical models, howev

111 The VMA intein, which encodes the PI-SceI endonuclease in Sa

112 al field: the HVA is less pronounced and the VMA is not present for children.

113 degrees at VMT, compared to the angle at the VMA stage.

114 cluded in the NMA group, and 21 knees in the VMA group.

115 11.31+/-6.67 and 6.86+/-7.58 letters in the VMA+ and VMA- groups, respectively (P = 0.007).

116 .81+/-132.31 and -161.84+/-131.34 mum in the VMA+ and VMA- groups, respectively (P = 0.681).

117 Here, to formally test the VMA, we have used the population density estimates obtai

118 Our results showed that the VMA law hold in felids, as well as the TL and the DMA la

119 Urinary VMA excretion, serum FGF23, and renal phosphate and calc

120 Remarkably, while VMA induced only transient hippocampal alterations, IVMA

121 llow-up (n = 60), 13.8 +/- 0.7 for eyes with VMA at baseline or follow-up (n = 79), and 12.9 +/- 0.4

122 Eyes with VMA were classified according to the diameter of vitreou

123 The safety of ocriplasmin in patients with VMA and wet AMD was shown to be comparable to the known

124 A total of 100 patients with VMA and wet AMD were randomized 3:1 to receive 125 mug o

125 Diabetic macular edema patients with VMA have a greater potential for improvement in visual o

126 nd point was the proportion of patients with VMA release at day 28 after injection.

127 The percentage of patients with VMA/VMT resolution at month 1 was higher than previously

128 novo CNV development in eyes with or without VMA.